Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic,Gastric, and Other Cancers.

Autor: Cardillo, Thomas M., Govindan, Serengulam V., Sharkey, Robert M., Trisal, Preeti, Arrojo, Roberto, Donglin Liu, Rossi, Edmund A., Chien-Hsing Chang, Goldenberg, David M.

Publikováno v: Bioconjugate Chemistry; May2015, Vol. 26 Issue 5, p919-931, 13p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.

Autor: Cardillo TM; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Zalath MB; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Arrojo R; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Sharkey RM; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Govindan SV; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Chang CH; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; At the time the work was conducted, all the authors were employees of Immunomedics, Inc., Goldenberg DM; Immunomedics, Inc., Morris Plains, NJ 07950 now acquired by Gilead Sciences, Inc., Foster City, CA 94404, USA.; Current address: Center for Molecular Medicine and Immunology, Mendham, NJ 07945, USA; E-mail, dmg.gscancer@att.net.; At the time the work was conducted, this author was Chairman and Chief Scientific Officer of Immunomedics, Inc., which he founded in 1982.

Publikováno v: Oncotarget [Oncotarget] 2024 Feb 22; Vol. 15, pp. 144-158. Date of Electronic Publication: 2024 Feb 22.